Date: 2017-05-31
Type of information: Private placement
Company: Achaogen (USA - CA)
Investors:
Amount: $105.4 million
Funding type: IPO
Planned used: Achaogen currently expects to use the net proceeds from this offering to fund its ongoing development and preparation for potential commercialization of plazomicin, including funding for plazomicin manufacturing, research and development of its C-Scape program, and any remaining proceeds for working capital and general corporate purposes, including research and development of its other product candidates.
Others:
- • On May 31, 2017, Achaogen announced the completion of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.50 per share. All shares in the offering were sold by Achaogen, with gross proceeds to Achaogen of approximately $112.5 million and net proceeds of approximately $105.4 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Achaogen has granted the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
- • On May 25, 2017, Achaogen announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $22.50 per share, for gross proceeds of $112.5 million before deducting underwriting discounts and commissions and offering expenses payable by Achaogen. In addition, Achaogen has granted the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 31, 2017, subject to satisfaction of customary closing conditions.
- • On May 23, 2017, Achaogen announced that it has commenced an underwritten public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Leerink Partners, Cowen and Stifel are acting as joint book-running managers for the offering.
Therapeutic area: Infectious diseases
Is general: Yes
